Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e95156255d5fe8b2923c544786e176 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
filingDate |
2018-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96b586fab3ea5eb46e1265a4af873b09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b138c13685caa232cd5c9cad6d631f86 |
publicationDate |
2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020046708-A1 |
titleOfInvention |
Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation |
abstract |
A method of reducing the severity of abdominal adhesion due to surgical complications comprising: administering to said patient at least a first dose of trametinib between 0.01 mg to 2.0 mg, and after said surgical procedure, administering to said patient a further dose of trametinib between 0.01 mg to 2.0 mg, daily, for at least seven days post-surgery. |
priorityDate |
2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |